A practical reference on melanocortin receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-04-01. Anything still debated is marked as such rather than presented as settled.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Alpha-MSH analogue with a lactam ring |
| Molecular formula | C50H69N15O9 | Commonly cited value for the neutral peptide |
| Molecular weight | 1024.18 g/mol | Calculated for the free molecule |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water, DMSO and ethanol | Dissolution in pure water is often slow |
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
However, the dependence on some of these properties is negligible in certain cases. For example, the viscosity of a Newtonian fluid does not vary significantly with the rate of deformation. Zero viscosity (no resistance to shear stress) is observed only at very low temperatures in superfluids; otherwise, the second law of thermodynamics requires all fluids to have positive viscosity. A fluid that has zero viscosity (non-viscous) is called ideal or inviscid. For non-Newtonian fluids' viscosity, there are pseudoplastic, plastic, and dilatant flows that are time-independent, and there are thixotropic and rheopectic flows that are time-dependent.
=== Aspartate === The biosynthesis of aspartate frequently involves the transamination of oxaloacetate. The enzyme aspartokinase, which catalyzes the phosphorylation of aspartate and initiates its conversion into other amino acids, can be broken up into 3 isozymes, AK-I, II and III. AK-I is feed-back inhibited by threonine, while AK-II and III are inhibited by lysine. As a sidenote, AK-III catalyzes the phosphorylation of aspartic acid that is the committed step in this biosynthetic pathway. Aspartate kinase becomes downregulated by the presence of threonine or lysine.
{\displaystyle {\begin{aligned}R_{*}&={\frac {\varepsilon }{D}}\cdot \mathrm {Re} {\sqrt {f_{\mathrm {D} }}}\cdot {\frac {1}{\sqrt {8}}}\\&={\frac {1}{2}}{\frac {\sqrt {g}}{\nu }}\varepsilon {\sqrt {S}}{\sqrt {D}}\end{aligned}}}
On January 8, 1850, a U.S. post office was established in Albany, with John Burkhart appointed as the first U.S. Postmaster. The town was renamed as "New Albany" on November 4, 1850, but the name was changed back to Albany in 1853. In 1851, Albany was designated as the county seat, replacing Calapooia (near modern-day Brownsville and Sweet Home), and all court meetings were held there. The first Albany courthouse was built in 1852 on 10 acres (4.0 ha) of land donated by the Monteiths to ensure Albany would remain the county seat. The new two-story octagonal courthouse was completed on April 26, 1853. The courthouse has since been replaced, but the new courthouse stands on the same site. During 1853–1854, residents of the east side of Albany persuaded the Oregon Legislative Assembly to name both towns Takenah. Though Takenah meant "deep pool," in reference to the confluence of the Calapooia and Willamette rivers, it was commonly translated as "Hole in the Ground". Partially due to this translation, the legislature restored the name Albany to the town in 1855. Finally in 1864, 16 years after the Monteiths founded the town and 19 years after the first European Americans arrived, it became incorporated as a city.
Sources: en.wikipedia.org
=== Microbial === Some molds such as Rhizomucor miehei are able to produce proteolytic enzymes. These molds are produced in a fermenter and then specially concentrated and purified to avoid contamination with unpleasant byproducts of the mold growth. The traditional view is that these coagulants result in bitterness and low yield in cheese, especially when aged for a long time. In modern times, microbial coagulants have improved greatly, largely due to the characterization and purification of secondary enzymes responsible for bitter peptide formation/non-specific proteolytic breakdown in cheese aged for long periods. Consequently, it has become possible to produce several high-quality cheeses with microbial rennet. It is also suitable for the elaboration of vegetarian cheese, provided no animal-based ingredients are used in its production.
An application of the Wittig-Still rearrangement in the context of natural product synthesis can be seen in Still's 1979 formal synthesis of the Cecropia juvenile hormone. The organotin-substituted ether that serves as the substrate for the rearrangement was readily prepared by bis-alkylation of the corresponding diol with iodomethyltributyltin. Treatment of this compound with two equivalents of n-butyllithium at low temperature resulted in transmetalation, initiating a double 2,3-sigmatropic rearrangement to give the bis-homoallylic alcohol product in 79% yield. Notably, this rearrangement is highly stereoselective with regard to the geometry of the trisubstituted olefins, giving exclusively the (Z,Z)-isomer shown.
For services to Higher Education. Carol Stump. Lately, President, Libraries Connected. For services to Public Libraries. Jacqueline Penelope Suttie. Founder and Chief Executive Officer, PTSD UK. For services to People with Post Traumatic Stress Disorder. Christopher Bennet Symonds. Senior Doorkeeper, House of Commons. For services to Parliament. Bolanle Tajudeen. Founder and Director, Bolanle Contemporary and Founder and Director, Black Blossoms. For services to the Arts. Deborah Janine Tann. Chief Executive, Hampshire and Isle of Wight Wildlife Trust. For services to Wildlife and the Natural Environment. Dr. Muhammad Saleem Khan Tareen. Psychiatrist, Northern Health and Social Care Trust. For services to Mental Ill Health and to Community Development in Northern Ireland. Jenny Thompson. Co-Founder and Director, Market Operations. For services to the Business and Food Sectors. Laurence Joseph Thraves. Head, National Situation Centre, Cabinet Office. For Public Service. Troy Donoghue Townsend. Head of Player Engagement, Kick It Out. For services to Diversity and Inclusion in Association Football. Deborah Ann Turnbull. Founder and Director, River and Sea Sense. For services to Water Safety Education for Young People and Families. Steven Underwood. Lately Mathematics Teacher, Ryedale School, Beadlam, North Yorkshire. For services to Education. Robin Arden Varley. Chair, Cricket Wales North Area Board, Cricket Wales Ltd. For services to Cricket in Wales. Sarah Vaughan. Deputy Head Teacher, Perryfields Primary Pupil Referral Unit, Worcester. For services to Education.
== Committees == CLSI documents are developed by committees consisting of experts in medical testing or related aspects. Each CLSI committee produces consensus documents related to a specific discipline.
Hydroxybenzotriazole (abbreviated HOBt) is an organic compound with the formula C6H4N3OH. It is a derivative of benzotriazole. It is a white crystalline powder, which as a commercial product contains some water (~11.7% wt as the HOBt monohydrate crystal). Anhydrous HOBt is explosive. It is mainly used to suppress the racemization and to improve the efficiency of peptide synthesis.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.
No national medicines agency has approved melanotan-2 for clinical use. Afamelanotide, a related but distinct peptide, holds a marketing authorisation in the European Union for a rare photosensitivity disorder. Melanotan-2 itself is handled as a laboratory chemical.
Its broad activity across melanocortin receptors makes it a tool for probing pigmentation, appetite and vascular signalling. Early trials recorded skin darkening and other effects that were not the original focus of the work. Those observations generated hypotheses that later studies have examined.
No. It is a synthetic analogue carrying four amino acid changes, a lactam ring and an amidated C-terminus. The natural hormone is a linear thirteen-amino-acid peptide processed from proopiomelanocortin.